TY - JOUR
T1 - Prevention of meningococcal disease
T2 - Current use of polysaccharide and conjugate vaccines
AU - Poland, Gregory A.
N1 - Funding Information:
Potential conflicts of interest. G.A.P. has received research funding from Merck, Novavax, Protein Sciences Corp, and Wyeth and has provided consultation for new vaccine development for Avianax, CSL Biotherapies, CSL Limited, Emergent Biosolutions, GlaxoSmithKline, Liquidia Technologies, Merck, Novartis Vaccines, Novavax, and PaxVax.
Funding Information:
Supplement sponsorship. This article was published as part of a supplement entitled “Immunization to Prevent Meningococcal Disease: Yesterday, Today, and Tomorrow,” which was sponsored by DIME and funded through an educational grant from Novartis Vaccines.
PY - 2010/3/1
Y1 - 2010/3/1
N2 - Invasive meningococcal disease (IMD), although uncommon, is difficult to diagnose and can be rapidly fatal, even in healthy young persons. IMD is cyclic, and serogroups responsible for disease vary by age group, although the prevalence of the serogroups changes over time and by geographical location. Two quadrivalent vaccines are licensed in the United States to prevent IMD caused by serogroups A, C, Y, and W-135, and the US Centers for Disease Control and Prevention recommends routine vaccination with quadrivalent meningococcal conjugate vaccine of adolescents 11-18 years of age and vaccination of persons 2-55 years of age who are at elevated risk of IMD. Efforts to prevent IMD remain challenging, because there is neither an immunogenic vaccine for infants nor a vaccine to prevent serogroup B disease that is currently licensed. Obstacles to achieving optimal vaccine coverage among adolescents persist, and strategies are needed to address these shortcomings.
AB - Invasive meningococcal disease (IMD), although uncommon, is difficult to diagnose and can be rapidly fatal, even in healthy young persons. IMD is cyclic, and serogroups responsible for disease vary by age group, although the prevalence of the serogroups changes over time and by geographical location. Two quadrivalent vaccines are licensed in the United States to prevent IMD caused by serogroups A, C, Y, and W-135, and the US Centers for Disease Control and Prevention recommends routine vaccination with quadrivalent meningococcal conjugate vaccine of adolescents 11-18 years of age and vaccination of persons 2-55 years of age who are at elevated risk of IMD. Efforts to prevent IMD remain challenging, because there is neither an immunogenic vaccine for infants nor a vaccine to prevent serogroup B disease that is currently licensed. Obstacles to achieving optimal vaccine coverage among adolescents persist, and strategies are needed to address these shortcomings.
UR - http://www.scopus.com/inward/record.url?scp=77951650463&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951650463&partnerID=8YFLogxK
U2 - 10.1086/648964
DO - 10.1086/648964
M3 - Review article
C2 - 20144016
AN - SCOPUS:77951650463
SN - 1058-4838
VL - 50
SP - S45-S53
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - SUPPL. 2
ER -